Review



bpde  (Toronto Research Chemicals)


Bioz Verified Symbol Toronto Research Chemicals is a verified supplier
Bioz Manufacturer Symbol Toronto Research Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Toronto Research Chemicals bpde
    Bpde, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bpde/product/Toronto Research Chemicals
    Average 93 stars, based on 1 article reviews
    bpde - by Bioz Stars, 2026-06
    93/100 stars

    Images



    Similar Products

    94
    Santa Cruz Biotechnology bpde
    Bpde, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bpde/product/Santa Cruz Biotechnology
    Average 94 stars, based on 1 article reviews
    bpde - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    86
    Cell Biolabs Inc oxiselecttm bpde dna adduct elisa kit
    Oxiselecttm Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/oxiselecttm bpde dna adduct elisa kit/product/Cell Biolabs Inc
    Average 86 stars, based on 1 article reviews
    oxiselecttm bpde dna adduct elisa kit - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    86
    Cell Biolabs Inc bpde dna adduct elisa kit
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Bpde Dna Adduct Elisa Kit, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bpde dna adduct elisa kit/product/Cell Biolabs Inc
    Average 86 stars, based on 1 article reviews
    bpde dna adduct elisa kit - by Bioz Stars, 2026-06
    86/100 stars
      Buy from Supplier

    93
    Toronto Research Chemicals bpde
    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation <t>between</t> <t>BPDE‐DNA</t> adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.
    Bpde, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bpde/product/Toronto Research Chemicals
    Average 93 stars, based on 1 article reviews
    bpde - by Bioz Stars, 2026-06
    93/100 stars
      Buy from Supplier

    94
    Santa Cruz Biotechnology benzo a pyrene diol epoxide bpde
    FIGURE 1 | Effects of S- and R-carvedilol on <t>BPDE-induced</t> lung epithelial cell transformation: Benzo(a)pyrene diol epoxide (BPDE), an active metabolite of B(a)P, was used to transform BEAS-2B cells. (A) & (B) The cells were pre-treated with 5 μM S- and R-carvedilol, 5 μM atenolol, 5 μM pro- pranolol (Prop), and 5 μM ICI-118551 (ICI) for 2 h, and then treated with 0.2 μM of BPDE for 1 h. The cells were then cultured with 5 μM of the drugs for 7 days. Afterward, they were seeded in soft agar in a 96-well plate (2000 cells/well) containing 5 μM of the drugs in the top layer of agar. The cell colonies were counted under a microscope after 10 days of incubation. (C) Representative images were taken using GelCount of the wells containing colonies that grew on agar after 10 days of incubation. The plotted data are represented as mean ± SD, n = 6 to 8. The one-way ANOVA followed by Dunnett's multiple comparison test was used to assess statistical differences. Statistical significance was denoted as ****: P < 0.0001 and **: P < 0.01.
    Benzo A Pyrene Diol Epoxide Bpde, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/benzo a pyrene diol epoxide bpde/product/Santa Cruz Biotechnology
    Average 94 stars, based on 1 article reviews
    benzo a pyrene diol epoxide bpde - by Bioz Stars, 2026-06
    94/100 stars
      Buy from Supplier

    Image Search Results


    A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation between BPDE‐DNA adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.

    Journal: Advanced Science

    Article Title: A Unique Chimeric RNA: ERCC1‐iASPP Drives Benzo[a]pyrene‐Induced Lung Carcinogenesis via Dual Coding and Non‐Coding Mechanisms

    doi: 10.1002/advs.202507217

    Figure Lengend Snippet: A novel oncogenic chimeric RNA ERCC1‐iASPP was found in lung cancer. A) Chimeric RNA ERCC1‐iASPP formation, schematic diagram of specific primer design, and peak melting curve. B) Agarose gel electrophoresis and Sanger sequencing determined the existence of ERCC1‐iASPP . C) 3'RACE, 5'RACE determined the full‐length sequence of ERCC1‐iASPP . D) mRNA expression of ERCC1‐iASPP in various cell lines, in which transformed malignant and lung cancer cells showed high expression levels. E) Primer design, PCR identification, and analysis of ERCC1 , iASPP intergenic region. F) miEAA analysis of ERCC1‐iASPP disease‐associated cloud plots. G) ERCC1‐iASPP expression levels in lung cancer tissues and their adjacent nonmalignant tissues (n = 60), comparing the differential expression of ERCC1‐iASPP in cancer tissues of 29 smokers and 31 non‐smokers, and categorizing lung cancer cases into non‐smokers (n = 31), light smokers (n = 7), moderate smokers (n = 14), and heavy smokers (n = 8) according to the number of pack‐years of smoking, and comparing them with the non‐smokers. The smoking group was compared to analyze changes in ERCC1‐iASPP expression. Pack‐years = (packs smoked per day) × (years as a smoker). H) Correlation between BPDE‐DNA adduct concentration (ng/mL) and ERCC1‐iASPP mRNA expression in tissues of smokers (n = 32). * P < 0.05, ** P < 0.01 and *** P < 0.001. ns: the difference is not statistically significant. Data represent the mean ± SD. D: n = 3, Student's t ‐test; G: Paired Samples t ‐test and Kruskal‐Wallis test; H: Pearson Correlation Test.

    Article Snippet: BPDE‐DNA adduct levels were quantified with the BPDE‐DNA Adduct ELISA Kit (Cell Biolabs, USA) according to the manufacturer's protocol.

    Techniques: Agarose Gel Electrophoresis, Sequencing, Expressing, Transformation Assay, Quantitative Proteomics, Concentration Assay

    FIGURE 1 | Effects of S- and R-carvedilol on BPDE-induced lung epithelial cell transformation: Benzo(a)pyrene diol epoxide (BPDE), an active metabolite of B(a)P, was used to transform BEAS-2B cells. (A) & (B) The cells were pre-treated with 5 μM S- and R-carvedilol, 5 μM atenolol, 5 μM pro- pranolol (Prop), and 5 μM ICI-118551 (ICI) for 2 h, and then treated with 0.2 μM of BPDE for 1 h. The cells were then cultured with 5 μM of the drugs for 7 days. Afterward, they were seeded in soft agar in a 96-well plate (2000 cells/well) containing 5 μM of the drugs in the top layer of agar. The cell colonies were counted under a microscope after 10 days of incubation. (C) Representative images were taken using GelCount of the wells containing colonies that grew on agar after 10 days of incubation. The plotted data are represented as mean ± SD, n = 6 to 8. The one-way ANOVA followed by Dunnett's multiple comparison test was used to assess statistical differences. Statistical significance was denoted as ****: P < 0.0001 and **: P < 0.01.

    Journal: Thoracic cancer

    Article Title: S- and R-Carvedilol Prevent Benzo(a)pyrene-Induced Lung Carcinogenesis.

    doi: 10.1111/1759-7714.70109

    Figure Lengend Snippet: FIGURE 1 | Effects of S- and R-carvedilol on BPDE-induced lung epithelial cell transformation: Benzo(a)pyrene diol epoxide (BPDE), an active metabolite of B(a)P, was used to transform BEAS-2B cells. (A) & (B) The cells were pre-treated with 5 μM S- and R-carvedilol, 5 μM atenolol, 5 μM pro- pranolol (Prop), and 5 μM ICI-118551 (ICI) for 2 h, and then treated with 0.2 μM of BPDE for 1 h. The cells were then cultured with 5 μM of the drugs for 7 days. Afterward, they were seeded in soft agar in a 96-well plate (2000 cells/well) containing 5 μM of the drugs in the top layer of agar. The cell colonies were counted under a microscope after 10 days of incubation. (C) Representative images were taken using GelCount of the wells containing colonies that grew on agar after 10 days of incubation. The plotted data are represented as mean ± SD, n = 6 to 8. The one-way ANOVA followed by Dunnett's multiple comparison test was used to assess statistical differences. Statistical significance was denoted as ****: P < 0.0001 and **: P < 0.01.

    Article Snippet: Benzo(a)pyrene was purchased from Sigma- Aldrich (St. Louis, MO), while Benzo(a)pyrene Diol Epoxide (BPDE) was obtained from Santa Cruz Biotechnology.

    Techniques: Transformation Assay, Cell Culture, Microscopy, Incubation, Comparison